Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 The results of the MR analysis between the 26 immune traits that reached suggestive significance and the risk of KSD

From: The immune factors have complex causal regulation effects on kidney stone disease: a mendelian randomization study

Exposure

Cell panel

Trait type

Outcome

Method

NO. of SNP

β

p-value

OR (95% CI)

q-value

CD28 on CD39 + CD4+

Treg

MFI

KSD

IVW

53

-0.039

3.70E-03

0.96 (0.94–0.99)

0.310

CD39 + CD4 + AC

Treg

Absolute count

KSD

IVW

27

-0.033

7.60E-03

0.97 (0.94–0.99)

0.422

CD25 + + CD8br %CD8br

Treg

Relative count

KSD

IVW

20

-0.048

0.027

0.95 (0.91–0.99)

0.735

CD39 + secreting Treg %CD4 Treg

Treg

Relative count

KSD

IVW

156

-0.015

0.030

0.99 (0.97-1.00)

0.618

CD25 on CD39 + CD4+

Treg

MFI

KSD

IVW

76

0.021

0.032

1.02 (1.00-1.04)

0.596

CD39 + secreting Treg %secreting Treg

Treg

Relative count

KSD

IVW

164

-0.014

0.038

0.99 (0.97-1.00)

0.527

CD28 + CD45RA + CD8dim %T cell

Treg

Relative count

KSD

IVW

53

0.013

0.038

1.01 (1.00-1.03)

0.578

CD28 + CD45RA + CD8br %T cell

Treg

Relative count

KSD

IVW

62

0.006

0.042

1.01 (1.00-1.01)

0.495

CD28- CD25 + + CD8br AC

Treg

Absolute count

KSD

IVW

20

0.030

0.042

1.03 (1.00-1.06)

0.537

CD39 on CD39 + secreting Treg

Treg

MFI

KSD

IVW

130

-0.014

0.043

0.99 (0.97-1.00)

0.480

CD3 on CD39 + CD4+

Treg

MFI

KSD

IVW

66

0.019

0.044

1.02 (1.00-1.04)

0.455

CD28- CD25 + + CD8br %T cell

Treg

Relative count

KSD

IVW

27

0.050

0.049

1.05 (1.00-1.11)

0.477

CD8 on HLA DR + CD8br

TBNK

MFI

KSD

IVW

29

-0.049

7.20E-04

0.95 (0.93–0.98)

0.088

CD8br NKT %lymphocyte

TBNK

Relative count

KSD

IVW

27

0.086

2.90E-03

1.09 (1.03–1.15)

0.180

HLA DR on HLA DR + CD8br

TBNK

MFI

KSD

IVW

18

-0.065

0.017

0.94 (0.89–0.99)

0.353

CD3- lymphocyte %leukocyte

TBNK

Relative count

KSD

IVW

18

0.046

0.031

1.05 (1.00-1.09)

0.548

CX3CR1 on CD14 + CD16 + monocyte

Monocyte

MFI

KSD

IVW

45

-0.031

0.015

0.97 (0.95–0.99)

0.612

CX3CR1 on CD14 + CD16- monocyte

Monocyte

MFI

KSD

IVW

42

-0.030

0.035

0.97 (0.94-1.00)

0.494

CD64 on CD14 + CD16- monocyte

Monocyte

MFI

KSD

IVW

83

0.019

0.040

1.02 (1.00-1.04)

0.422

TD DN (CD4-CD8-) %DN

Maturation stages of T cell

Relative count

KSD

IVW

30

-0.012

0.031

0.99 (0.98-1.00)

1.226

CCR2 on monocyte

cDC

MFI

KSD

IVW

36

0.044

2.50E-03

1.04 (1.02–1.07)

0.157

CCR2 on CD62L + myeloid DC

cDC

MFI

KSD

IVW

24

0.048

9.50E-03

1.05 (1.01–1.09)

0.301

IgD- CD38br %B cell

B cell

Relative count

KSD

IVW

12

-0.082

8.30E-03

0.92 (0.87–0.98)

0.142

CD27 on CD24 + CD27+

B cell

MFI

KSD

IVW

73

0.019

0.025

1.02 (1.00-1.04)

0.278

IgD- CD27- %lymphocyte

B cell

Relative count

KSD

IVW

18

-0.056

0.026

0.95 (0.90–0.99)

0.274

CD20 on memory B cell

B cell

MFI

KSD

IVW

46

-0.041

0.038

0.96 (0.92-1.00)

0.375

  1. MR, Mendelian randomization; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; IVW, inverse variance weighted.
Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us